X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10752) 10752
Newsletter (1487) 1487
Publication (970) 970
Newspaper Article (138) 138
Book Review (73) 73
Transcript (22) 22
Book Chapter (17) 17
Report (9) 9
Book / eBook (8) 8
Conference Proceeding (5) 5
Magazine Article (4) 4
Data Set (2) 2
Dissertation (2) 2
Paper (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anthracyclines (9486) 9486
humans (6975) 6975
index medicus (6524) 6524
cancer (5885) 5885
chemotherapy (4965) 4965
female (4738) 4738
oncology (4117) 4117
doxorubicin (3913) 3913
middle aged (2766) 2766
animals (2714) 2714
male (2631) 2631
adult (2431) 2431
breast cancer (2362) 2362
doxorubicin - administration & dosage (2318) 2318
aged (2304) 2304
antineoplastic combined chemotherapy protocols - therapeutic use (2195) 2195
analysis (2187) 2187
care and treatment (2181) 2181
breast neoplasms - drug therapy (2131) 2131
research (2115) 2115
pharmacology & pharmacy (2057) 2057
drugs (1995) 1995
treatment outcome (1670) 1670
drug delivery systems (1637) 1637
therapy (1446) 1446
mice (1423) 1423
anthracycline (1401) 1401
medicine & public health (1337) 1337
cell line, tumor (1325) 1325
vehicles (1300) 1300
tumors (1278) 1278
nanoparticles (1266) 1266
health aspects (1227) 1227
breast neoplasms - pathology (1221) 1221
cardiotoxicity (1160) 1160
cyclophosphamide (1128) 1128
antibiotics, antineoplastic - administration & dosage (1079) 1079
apoptosis (1077) 1077
anthracyclines - administration & dosage (1072) 1072
drug therapy (1067) 1067
doxorubicin - pharmacology (1054) 1054
antineoplastic combined chemotherapy protocols - adverse effects (1009) 1009
hematology (978) 978
toxicity (973) 973
oncology, experimental (944) 944
metastasis (903) 903
paclitaxel (862) 862
antineoplastic agents - administration & dosage (843) 843
antineoplastic agents - therapeutic use (842) 842
rats (811) 811
antineoplastic combined chemotherapy protocols - administration & dosage (796) 796
disease-free survival (784) 784
doxorubicin - therapeutic use (783) 783
doxorubicin - adverse effects (763) 763
anthracyclines - adverse effects (737) 737
neoplasms - drug therapy (732) 732
clinical trials (719) 719
dosage and administration (713) 713
dose-response relationship, drug (711) 711
prognosis (711) 711
doxorubicin - chemistry (710) 710
survival (688) 688
retrospective studies (680) 680
cancer therapies (675) 675
in-vitro (649) 649
antineoplastic agents - adverse effects (642) 642
cyclophosphamide - administration & dosage (634) 634
drug-delivery (629) 629
reports (628) 628
aged, 80 and over (625) 625
risk factors (622) 622
hematology, oncology and palliative medicine (614) 614
taxoids - administration & dosage (605) 605
cells (598) 598
adolescent (597) 597
adriamycin (595) 595
anthracyclines - therapeutic use (594) 594
breast-cancer (594) 594
docetaxel (590) 590
neoplasm staging (590) 590
doxorubicin - pharmacokinetics (588) 588
antineoplastic agents - pharmacology (580) 580
materials science, biomaterials (573) 573
drug administration schedule (570) 570
article (564) 564
medical research (563) 563
expression (559) 559
cytotoxicity (558) 558
chemistry, multidisciplinary (556) 556
cell survival - drug effects (551) 551
drug delivery (549) 549
pharmacology/toxicology (549) 549
apoptosis - drug effects (539) 539
liposomes (539) 539
oxidative stress (538) 538
epirubicin (534) 534
trastuzumab (533) 533
cancer research (531) 531
trial (531) 531
tumor (527) 527
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12230) 12230
Japanese (58) 58
French (40) 40
Chinese (24) 24
Russian (24) 24
German (16) 16
Italian (11) 11
Polish (10) 10
Spanish (8) 8
Hungarian (5) 5
Czech (4) 4
Portuguese (4) 4
Danish (2) 2
Arabic (1) 1
Finnish (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2017, Volume 2017, Issue 8, pp. CD004064 - CD004064
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article
Jnci-Journal of the national cancer institute, ISSN 0027-8874, 10/2016, Volume 108, Issue 10, p. djw166
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 6/2013, Volume 21, Issue 6, pp. 1655 - 1663
Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an... 
Breakthrough nausea and emesis | Pain Medicine | Chemotherapy | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Oncology | Metoclopramide | Nursing Management/Nursing Research | DEXAMETHASONE | PREVENTION | APREPITANT | ANTIEMETIC ACTIVITY | CANCER-PATIENTS | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PALONOSETRON | QUALITY-OF-LIFE | DELAYED NAUSEA | CISPLATIN-INDUCED EMESIS | Cyclophosphamide - administration & dosage | Isoquinolines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Nausea - drug therapy | Vomiting - prevention & control | Quinuclidines - adverse effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Metoclopramide - administration & dosage | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Metoclopramide - adverse effects | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Isoquinolines - administration & dosage | Doxorubicin - adverse effects | Care and treatment | Cyclophosphamide | Anthracyclines | Dexamethasone | Nausea | Cancer | Side effects | Drug therapy | Vomiting | Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2016, Volume 229, pp. 183 - 191
Functional nanocarriers capable of transporting high drug contents without premature leakage and to controllably deliver several drugs are needed for better... 
Mesoporous silica nanoparticles | Multi-drug delivery | Bovine serum albumin | Gold nanoclusters | Cancer | BRIDGED SILSESQUIOXANE NANOPARTICLES | VITRO | PEGYLATED LIPOSOMAL DOXORUBICIN | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | GEMCITABINE | BREAST-CANCER | NANOCLUSTERS | RESPONSIVE CONTROLLED-RELEASE | FLUORESCENT-PROBES | PHARMACOLOGY & PHARMACY | ORGANOSILICA NANOPARTICLES | Silicon Dioxide - administration & dosage | Deoxycytidine - chemistry | Gold - administration & dosage | Nanocomposites - chemistry | Nanoparticles - chemistry | Serum Albumin, Bovine - administration & dosage | Humans | Drug Carriers - administration & dosage | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Serum Albumin, Bovine - chemistry | Doxorubicin - administration & dosage | Gold - chemistry | A549 Cells | Cell Line | Deoxycytidine - administration & dosage | Silicon Dioxide - chemistry | Antineoplastic Agents - chemistry | Neoplasms - diagnostic imaging | Neoplasms - drug therapy | Drug Liberation | Nanoparticles - administration & dosage | Porosity | Deoxycytidine - analogs & derivatives | Nanocomposites - administration & dosage | Nanoparticles | Drugs | Albumin | Precious metal products | Silica | Tumors | Drug delivery systems | Anthracyclines | Pharmaceutical industry | Vehicles
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2013, Volume 31, Issue 7, pp. 860 - 867
Journal Article